



Detecting and managing subclinical hyperthyroidism

HUSSEIN SAADI, MD, FACP

Departments of General Internal Medicine and Endocrinology, Cleveland Clinic.

SINCE THE LATE 1980s, when sensitive thyroid-stimulating hormone (TSH) assays were introduced, the serum TSH level has become the single best test of thyroid function. Now that physicians are using TSH assays more widely, they are encountering subclinical thyroid disease more frequently. In most cases, low TSH values either normalize spontaneously or are due to thyroid hormone therapy, but some reflect conditions that require further workup and management.

■ DEFINITION: LOW TSH, NORMAL T₃ AND T₄

Subclinical hyperthyroidism is generally defined as the combination of all three of the following:

- A TSH level less than 0.1 mU/L (normal 0.4–5.0 mU/L);
- A normal free thyroxine (FT₄) level (0.7–1.8 ng/dL) or a normal free T₄ index (6.4–10.7 µg/dL); and
- A normal triiodothyronine (T₃) level (94–170 ng/dL).

Low serum TSH concentrations may frequently be transient. Among 66 patients with subclinical hyperthyroidism in a British general practice, 40 (61%) had normal concentrations 1 year later.¹ In another study in a primary care center in Sweden, of 53 clinically euthyroid patients who had low serum TSH concentrations, 27 (53%) had normal values 2 to 3 weeks later.²

■ CAUSES OF SUBCLINICAL HYPERTHYROIDISM

Patients may or may not have symptoms. In all cases, causes of low TSH unrelated to hyperthyroidism should be excluded: nonthyroid illnesses, secondary (pituitary) hypothyroidism, central (hypothalamic) hypothyroidism, recovery from hyperthyroidism, drugs (glucocorticoids, dopamine agonists), and spurious test results.

Exogenous thyroid hormone therapy is the most common cause of subclinical hyperthyroidism. Other important causes are:

- Multinodular goiter.
- Solitary (autonomous) thyroid adenoma.
- Subclinical Graves' disease.
- Subacute thyroiditis with transient hyperthyroidism.
- Silent (postpartum) thyroiditis.

■ CONSEQUENCES OF SUBCLINICAL HYPERTHYROIDISM

Cardiac effects of subclinical hyperthyroidism include atrial fibrillation, frequent atrial premature contractions, sinus tachycardia, and increased left ventricular mass and contractility.³ Sawin et al⁴ followed 2,007 subjects 60 years of age or older for up to 10 years and, after adjusting for other risk factors, found that the risk of developing atrial fibrillation was approximately three-fold higher in persons with serum TSH levels ≤ 0.1 mU/L than in those with normal concentrations.

Accelerated bone loss, another potential problem of subclinical hyperthyroidism, is caused by increased bone resorption, especially in postmenopausal women who are not receiving estrogen replacement therapy.^{5,6}

Other possible consequences of subclinical hyperthyroidism include increased serum glutathione S-transferase activity, decreased serum creatine kinase activity, and increased sex hormone-binding globulin levels.

The serum TSH level is the single best test of thyroid function


MANAGING SUBCLINICAL HYPERTHYROIDISM

In hypothyroid patients receiving thyroid replacement therapy, the TSH level should be maintained in the normal range. There is probably no need to reduce the dosage in a patient whose serum TSH concentration is only slightly low (ie, 0.25–0.4 mU/L), as there may be some daily fluctuations in TSH levels, and the risks of slightly low values in otherwise-healthy patients is negligible. In addition, frequent manipulations of the dosage may complicate therapy and increase cost.

In patients receiving suppressive treatment for thyroid cancer or benign thyroid disease, the TSH level should be maintained between 0.1 and 0.4 mU/L, unless the patient has aggressive thyroid cancer, in which case the TSH level should be suppressed to undetectable levels (< 0.02 mU/L). In these patients, consideration should be given to the concurrent administration of cardioselective beta blockers, which have been shown to ameliorate most of the cardiac effects of subclinical hyperthyroidism.^{7,8}

In asymptomatic patients with endogenous subclinical hyperthyroidism, one should recheck the TSH level and also check the T_3 level and either the free T_4 level or the free T_4 index. If the T_4 and T_3 levels are normal, then the TSH level should be checked again in 2 to 3 months and then every 6 months. If the TSH level is persistently less than 0.1 mU/L or the patient has conditions to which small degrees of thyroid hormone excess might contribute (eg, atrial fibrillation, other atrial arrhythmias, other cardiac disorders, or accelerated bone loss), further workup and management is necessary.

Twenty-four hour radioactive iodine uptake and scanning may help differentiate between subacute thyroiditis with transient hyperthyroidism (in which the uptake is undetectable, and the natural history is characterized by spontaneous remission) vs conditions that are characterized by high radioactive iodine uptake. These latter conditions include a “hot” nodule (toxic adenoma), toxic diffuse goiter (Graves’ disease), or toxic multinodular goiter. Since these latter condi-

tions almost always persist, one should consider treating them with antithyroid medications, radioactive iodine, or surgery. 

REFERENCES

1. Parle JV, Franklyn JA, Cross KW, Jones SC, Sheppard MC. Prevalence and follow-up of abnormal thyrotropin (TSH) concentrations in the elderly in the United Kingdom. *Clin Endocrinol (Oxf)* 1991; 34:77–83.
2. Eggertsen R, Petersen K, Lundberg PA, Nystrom E, Lindstedt G. Screening for thyroid disease in a primary care unit with a thyroid stimulating hormone assay with a low detection limit. *Br Med J* 1988; 297:1586–1592.
3. Biondi B, Fazio S, Carella C, et al. Cardiac effects of long-term thyrotropin-suppressive therapy with levothyroxine. *J Clin Endocrinol Metab* 1993; 77:334–338.
4. Sawin CT, Geller A, Wolf PA, et al. Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. *N Engl J Med* 1994; 331:1249–1252.
5. Faber J, Galloe AM. Prolonged subclinical hyperthyroidism due to L-thyroxine treatment: a meta-analysis. *Eur J Endocrinol* 1994; 130:350–356.
6. Schneider DL, Barrett-Connor EL, Morton DJ. Thyroid hormone use and bone mineral density in elderly women: effects of estrogen. *JAMA* 1994; 271:1245–1249.
7. Biondi B, Fazio S, Carella C, et al. Control of adrenergic overactivity by β -blockade improves the quality of life in patients receiving long-term suppressive therapy with levothyroxine. *J Clin Endocrinol Metab* 1994; 77:1028–1033.
8. Fazio S, Biondi B, Carella C, et al. Diastolic dysfunction in patients on thyroid-stimulating hormone suppressive therapy with levothyroxine: beneficial effect of β -blockade. *J Clin Endocrinol Metab* 1995; 80:2222–2226.

Understanding culture clashes in the clinical setting

JACQUELYN SLOMKA, PhD, RN

Department of Bioethics, the Cleveland Clinic.

IN OUR DIVERSE SOCIETY it is not unusual for physicians to encounter patients and colleagues from a cultural, ethnic, or religious background different from their own. Such differences are often ignored or are only of passing interest when the clinical or collegial encounter is free of problems. For the most part, we assume that other people understand us and that we understand them.

However, occasionally conflict can surface in the form of a “difficult” patient, an “unreasonable” colleague, or a family member who

Thyroid hormone therapy is the most common cause of subclinical hyperthyroidism